Within North America, we are seeing what we at Emerson lightly refer to as a ‘Reverse Generic Wave’ of overseas generics manufacturers building secondary and finishing facilities to sell products in the local market to meet local regulations.
This market shift might be accelerated further by a new bipartisan bill introduced late last week in the U.S. The Fair Access for Safe and Timely (FAST) Generics Act aims to close loopholes that allow brand name drug companies to deny their generic rivals access to their formulas for necessary testing and, ultimately, FDA approval.
Good news for consumers – More access to affordable, life-saving medications.
I’m curious how you think closing the loopholes will affect brand name and generics manufacturers?
You can read more about it here: http://blogs.wsj.com/pharmalot/2015/06/23/a-bill-would-prevent-drug-makers-from-frustrating-generic-rivals/?mod=WSJBlog